Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Blinatumomab-Related ICANS Symptoms More Prevalent Than Prior Reports

April 11, 2025
By Russ Conroy
Fact checked by" Roman Fabbricatore
News
Article
Conference|Oncology Nursing Society’s Annual Meeting (ONS)

An objective assessment tool like the ICE Score may standardize grading of neurotoxicity associated with newer bispecific antibodies in hematologic cancer.

“Utilizing an objective assessment tool, such as the Immune Effector Cell Encephalopathy [ICE] Score, would standardize nursing assessment and grading of neurotoxicity like newer bispecific antibodies and potentially prevent treatment interruptions due to more mild symptoms," according to study author Jessica [RC1] Miles, MS, RN, CNS, AOCNS, BMTCN.

“Utilizing an objective assessment tool, such as the Immune Effector Cell Encephalopathy [ICE] Score, would standardize nursing assessment and grading of neurotoxicity like newer bispecific antibodies and potentially prevent treatment interruptions due to more mild symptoms," according to study author Jessica [RC1] Miles, MS, RN, CNS, AOCNS, BMTCN.

The incidence of symptoms consistent with immune effector cell-associated neurotoxicity syndrome (ICANS) following treatment with blinatumomab (Blincyto) was found to be higher than what prior reports demonstrated, according to findings from a poster presentation at the 50th Annual Oncology Nursing Society Conference.1

Of 28 patients who received blinatumomab, 57% experienced any neurotoxicity, and 46% had any aphasia and/or encephalopathy. Approximately 25% of aphasia and/or encephalopathy events were grade 3.

Data showed that the most common neurotoxicity symptoms included headache (69%), encephalopathy (69%), tremors (63%), and aphasia (38%). Additionally, dizziness and paresthesia occurred in 19% and 13% of patients, respectively.

Regarding toxicity intervention strategies, investigators stopped blinatumomab infusion for an equal proportion of patients with grade 2 and grade 3 events. However, initiating prophylaxis with steroids was more common for patients with grade 2 toxicities compared with those who had grade 3 events.

“Our study population experienced a higher rate of symptoms consistent with ICANS compared to what has been reported. Implementation of interventions was not consistent between grade 2 and grade 3 symptoms,” lead study author Jessica Miles, MS, RN, CNS, AOCNS, BMTCN, a clinical nurse specialist in oncology at University of California Davis Medical Center, wrote with coauthors.1 “Utilizing an objective assessment tool, such as the Immune Effector Cell Encephalopathy [ICE] Score, would standardize nursing assessment and grading of neurotoxicity like newer bispecific antibodies and potentially prevent treatment interruptions due to more mild symptoms.”

Regarding the study’s rationale, investigators noted that bispecific antibodies like blinatumomab are known to cause ICANS, which is graded using the ICE Score as a screening and diagnosis standard. ICANS, however, was defined following the approval of blinatumomab and not included in studies assessing treatment with the bispecific antibody.

According to the 2024 prescribing information for blinatumomab, the rate of signs and symptoms consistent with ICANS was 7.5% in clinical trials evaluating the agent.2 Additionally, the label recommends withholding treatment with blinatumomab in the event of grade 3 neurotoxicity.

Based on this context, investigators aimed to evaluate the incidence and symptoms of neurotoxicity related to blinatumomab while identifying patterns in interventions for mitigating these toxicities. As part of a retrospective cohort study, investigators assessed adult patients who underwent treatment with blinatumomab between 2020 and 2023. Data evaluation involved an electronic record review, and investigators used descriptive statistics to analyze patient outcomes.

According to the prescribing information for blinatumomab, the FDA initially approved the agent for intravenous use in 2014. The anti-CD19 T-cell engager is indicated for use in adult and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) expression of at least 0.1% and those with relapsed/refractory CD19-positive B-cell precursor ALL.

Blinatumomab is contraindicated for patients with known hypersensitivity to the agent or any of its components. Additionally, the labelling includes warnings and precautions for the possibility of cytokine release syndrome, ICANS, infections, tumor lysis syndrome, neutropenia, elevated pancreatitis, leukoencephalopathy, and embryo-fetal toxicity.

Investigators assessed the efficacy of blinatumomab for patients with MRD-positive B-cell precursor ALL in the BLAST study (NCT01207388). Overall, 70 patients (81.4%; 95% CI, 71.6%-89.0%) achieved undetectable MRD, and the median hematological relapse-free survival was 22.3 months.

The open-label TOWER study (NCT02013167) evaluated blinatumomab vs standard-of-care chemotherapy among patients with relapsed/refractory B-cell precursor ALL.Data showed a median overall survival of 7.7 months (95% CI, 5.6-9.6) with blinatumomab vs 4.0 months (95% CI, 2.9-5.3) with chemotherapy (HR, 0.71; 95% CI, 0.55-0.93; P = .012).

References

  1. Miles J. Unraveling blinatumomab-associated neurotoxicity: incidence and interventions. Presented at the 50th Annual Oncology Nursing Society Conference; April 9-13, 2025; Denver, CO. Poster RS104.
  2. BLINCYTO® (blinatumomab) for injection, for intravenous use. Prescribing information. FDA; 2024. Accessed April 8, 2025. https://tinyurl.com/3y9fx5ms
Recent Videos
Predictors of response have a significant effect on clinical decision-making because they may help oncologists select the best treatment for specific patients.
Delaying treatment with ruxolitinib by more than a year leads to decreased response rates and overall survival in patients with myelofibrosis.
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
Related Content
Advertisement

We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Tim Cortese
September 11th 2025
Article

Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Ariana Pelosci
September 10th 2025
Article

Results from the DeLLphi-303 trial showed sustained efficacy and safety with tarlatamab plus anti–PD-1 treatment for patients with extensive-stage SCLC.


We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 10th 2025
Article

According to Sundar Jagannath, MBBS, the cure for multiple myeloma was observed in patients who were cancer free for 5 years without maintenance therapy.

Related Content
Advertisement

We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Tim Cortese
September 11th 2025
Article

Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Ariana Pelosci
September 10th 2025
Article

Results from the DeLLphi-303 trial showed sustained efficacy and safety with tarlatamab plus anti–PD-1 treatment for patients with extensive-stage SCLC.


We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 10th 2025
Article

According to Sundar Jagannath, MBBS, the cure for multiple myeloma was observed in patients who were cancer free for 5 years without maintenance therapy.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.